Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone

American Journal of Psychiatry

Volumn 157, Issue 7, 2000, Pages 1150-1155

  Jeste, Dilip V ^b   Okamoto, Akiko ^b   Napolitano, Judy ^b   Kane, John M ^b   Martinez, Rick A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

AGED; AGING; ARTICLE; CLINICAL TRIAL; DEMENTIA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DEMENTIA; DEMENTIA, VASCULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PLACEBOS; RISPERIDONE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033929228     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.7.1150     Document Type: Article

References (25)

1. American Psychiatric Association Task Force Report 18: Tardive Dyskinesia. Washington, DC, APA, 1980
2. Yassa R, Jeste DV: Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18:701-715
3. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA: Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995; 52:756-765
4. Kane JM, Woerner M, Lieberman JA, Kinon BJ: Tardive dyskinesia and drugs, in New Approaches to the Development of Anti-Schizophrenic Drugs: Proceedings of a Symposium (Drug Development Research Series, vol 9). Edited by Cornfeldt ML, Shutske GM. New York, Alan R Liss, 1986, pp 41-51
5. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP: Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999; 156:309-311
6. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, Blank K, Koblenzer J, Kahaner K: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402-2406
7. Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM: Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155:1521-1528
8. Lemmens P, Brecher M, Van Baelen B: A combined analysis of double-blind studies with risperidone versus placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999; 99:160-170
9. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60:107-115
10. Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal symptom rating scale (letter). Can J Neurol Sci 1980; 7:233
11. Simpson GM, Lindenmayer JP: Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17:194-201
12. Peuskens J (Risperidone Study Group): Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712-726
13. Reisberg B: Functional Assessment Staging (FAST). Psychopharmacol Bull 1988; 24:653-659
14. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
15. Reisberg B, Borenstein J, Salob SP, Ferris S, Franssen E, Georgotas A: Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48:9-15
16. Schooler NR, KaneJM: Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 1982; 39:486-487
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statistical Assoc 1958; 53:457-481
18. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
19. Jeste DV, Lacro JP, Nguyen HA, Petersen ME, Rockwell E, Sewell DD, Caligiuri MP: Incidence of tardive dyskinesia with risperidone versus haloperidol. J Am Geriatr Soc 1999; 47:716-719
20. Chouinard G: Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15(Feb suppl 1):36S-44S
21. Khan BU: Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. J Autism Dev Disord 1997; 27:479-489
22. Lieberman JA, Saltz BL, Johns CA, Pollacks, Borenstein M, Kane J: The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158:503-510
23. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248-1254
24. De Deyn P, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PLJ, Eriksson S, Lawlor BA: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53:945-955
25. Patterson TL, Kaplan RM, Grant I, Semple SJ, Moscona S, Koch WL, Harris MJ, Jeste DV: Quality of well-being in late-life psychosis. Psychiatry Res 1996; 63:169-181